Chardan Capital Reiterates Buy on Regenxbio, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Daniil Gataulin has reiterated a 'Buy' rating on Regenxbio (NASDAQ:RGNX) and maintained a price target of $55.
August 04, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regenxbio's stock may see positive movement as Chardan Capital maintains a 'Buy' rating and a $55 price target.
Analyst ratings often influence the market's perception of a stock. In this case, Chardan Capital's reiteration of a 'Buy' rating and a $55 price target for Regenxbio could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100